Global drug manufacturers are applying pressure to European governments over medicine pricing policies — and they appear to be borrowing a strategy that recently worked in the United Kingdom: threatening to withdraw investment unless policymakers back down.
Germany has become the primary focus of that pressure. The country is currently debating legislation aimed at reining in rapidly rising costs within its public health insurance system. The pharmaceutical industry scored a notable victory in Britain after the government agreed to increase medicine spending as part of a broader arrangement designed to avoid tariffs imposed by Washington.
Pfizer sent a letter last week to the German chancellor warning that its investments in the country were at risk because of the proposed drug-pricing policy. AstraZeneca cautioned that it might not introduce new medications in Germany if the legislation moves forward.
Earlier this month, Eli Lilly announced it would cut a planned 2.3 billion euro ($2.7 billion) investment in half. Germany-based Boehringer Ingelheim separately announced it was canceling expansion plans valued at 900 million euros. Both companies pointed to the proposed legislation as the reason.
Diarmaid MacDonald of Just Treatment, a patient advocacy group based in the UK, was critical of the industry’s approach. “The industry is delighted with how the UK government folded in the face of their pressure,” he said. “They would love to see others replicate that capitulation.”
Germany’s health ministry said this week that no final decisions had been made and declined to elaborate on any ongoing parliamentary discussions.
The pressure appears to be having some effect. A government source told Reuters on Monday that Germany would abandon part of the plan the industry objected to, replacing a variable discount system with a fixed one to reduce the investment uncertainty that companies had flagged.
However, industry sources indicated that change alone does not resolve their wider concerns about Germany’s pricing environment. The proposed law still faces months of parliamentary debate and could undergo further revisions.
Those same sources said the UK agreement was seen favorably by drugmakers not just because of changes to how new medicines are valued and paid for, but also because it included commitments around innovation and patient access.
Healthcare analyst Diederik Stadig of ING Bank noted that the industry’s response in Germany appeared more reactive compared to what he described as a more deliberate strategy in Britain, though he acknowledged the two situations were comparable.
“The German government made a proposal, ‘we want to reform pricing’. And the industry said, ‘OK, that’s all well and good, but that affects our return on investment,’” Stadig said. He added that factors including tariffs, U.S. pricing policy, the rise of China, and the attractiveness of the American market were all making Europe a less appealing destination for pharmaceutical investment. “The industry is making Europe acutely aware of this,” he said.
The dispute in Germany is part of a wider conflict playing out across the continent. In France, the national health authority accused drugmakers in April of using what it called “coercive pressure” to influence clinical assessments, including threats to pull medicines from the market. In the Netherlands, the country’s biotech lobby warned that companies were growing more hesitant about seeking drug reimbursement approvals and that the country risked falling lower on pharmaceutical launch priority lists.
Adding to the tension is the impact of U.S. President Donald Trump’s most-favored-nation pricing initiative, which seeks to link prescription drug prices in the U.S. market to lower prices charged in other countries, including in Europe. Several major drug companies have already reached agreements with the White House to reduce U.S. drug costs in exchange for tariff relief, which is creating additional pressure to raise prices in other markets.
Some critics viewed Germany’s partial concession as a concerning sign of how much leverage the pharmaceutical industry currently holds. At the same time, they noted that European nations retain some bargaining power, since the continent remains a significant market even if it is less profitable than the United States.
Sally Gainsbury, an analyst at the healthcare think tank Nuffield Trust, offered a measured perspective. “America is not the only market in the world,” she said, while acknowledging that the UK-U.S. pricing agreement carried a cautionary message for Europe. “The depressing reality is that the ‘UK playbook’ here means health systems will spend more, but will get less health benefit for their populations,” she added.
